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BACKGROUND: Animal and plant MMPs are kept 
zymogenic through large pro-domains and a cysteine-
switch mechanism. 
RESULTS: Bacterial MMP karilysin has only a short N-
terminal peptide upstream of the catalytic domain, which 
lacks cysteines. 
CONCLUSION: This peptide inhibits through an 
aspartate-switch mechanism and also exerts other functions 
of authentic pro-domains. 
SIGNIFICANCE: Karilysin is kept latent by a novel 
mechanism for MMPs. 
ABSTRACT 
The matrix metalloproteinases  (MMPs) are a 
family of secreted soluble or membrane-anchored 
multi-modular peptidases regularly found in several 
paralogous copies in animals and plants, where they 
have multiple functions. The minimal consensus domain 
architecture comprises a signal peptide, a 60-to-90-
residue globular pro-domain with a conserved sequence 
motif including a cysteine engaged in “cysteine-switch” 
or “Velcro” mediated latency, and a catalytic domain. 
Karilysin, from the human periodontopathogen 
Tannerella forsythia, is the only bacterial MMP to have 
been characterized biochemically to date. It shares with 
eukaryotic forms the catalytic domain but none of the 
flanking domains. Instead of the consensus MMP pro-
domain, it features a 14-residue pro-peptide—the 
shortest reported for a metallopeptidase—, which lacks 
cysteines. Here we determined the structure of a pro-
karilysin fragment encompassing the pro-peptide and 
the catalytic domain, and found that the former runs 
across the cleft in the opposite direction to a bound 
substrate and inhibits the latter through an “aspartate-
switch” mechanism. This finding is reminiscent of 
latency maintenance in the otherwise unrelated astacin 
and fragilysin metallopeptidase families. In addition, in 
vivo and biochemical assays showed that the pro-
peptide contributes to protein folding and stability. Our 
analysis of pro-karilysin reveals a novel mechanism of 
latency and activation in MMPs. Finally, our findings 
support the view that the karilysin catalytic domain was 
co-opted by competent bacteria through horizontal gene 
transfer from a eukaryotic source, and later evolved in 
a specific bacterial environment. 
INTRODUCTION 
The matrix metalloproteinases (MMPs) are a family 
of zinc- and calcium-dependent peptidases, which are 
grouped into the metzincin clan of metallopeptidases (MPs) 
together with other separate families such as the 
ADAMs/adamalysins, astacins, fragilysins, and serralysins 
(1-8). MMPs are found throughout animals and plants (9-
12), where their distribution is consistent with a Darwinian 
tree-based pathway. In addition, polyplication has led to 
several paralogous MMP genes being present in the same 
organism: 24 in humans, 26 in sea urchin, 26 in zebra fish, 
seven in sea squirt and two in fruitfly (11). In contrast, only 
a patchy phylogenetic distribution of genes encoding 
hypothetical orthologs has been found in viruses, Bacteria, 
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Archaea and fungi. Earlier studies of the relationship 
between mammalian MMPs and supposed prokaryotic 
orthologs included—as we now know—bacterial members 
of other metzincin families such as serralysins, fragilysins, 
and astacins (13-16). Accordingly, it was suggested that a 
primordial MMP may have arisen from an ancestor that is 
common to vertebrates, invertebrates and plants but is not 
shared by earlier stages in evolution (11,16-18). This 
entails that the hypothetical prokaryotic, viral, and fungal 
MMPs are incongruent with the tree of life or, more 
accurately, xenologs, i.e. the result of direct or indirect 
horizontal gene transfer from eukaryotic donors (9,19,20). 
This is reminiscent of the evolutionary origin postulated for 
fragilysin, which is the only molecular virulence factor 
described for enterotoxigenic Bacteroides fragilis and for 
which no similar proteins have been reported, not even 
from other B. fragilis strains (21). Structural studies 
supported the view that the catalytic domain of this MP is 
the result of horizontal gene transfer of a member of the 
ADAM/adamalysin family, which has 38 orthologs in 
humans (8,22-25), from a mammalian host to this 
bacterium, which thrives in the intestinal tract (26,27).  
Returning to MMPs, karilysin from the human 
periodontopathogen Tannerella forsythia is the only 
bacterial family member to have been analyzed 
biochemically to date (9,28-33). In addition to karilysin, 
only MmpZ from Bacillus anthracis has been functionally 
assessed at the genetic level through knock-out studies in 
B. anthracis cells, but it has not been isolated or 
characterized (34). Similarly to vertebrate MMPs, karilysin 
showed preference for medium-sized to bulky hydrophobic 
residues (leucine, tyrosine and methionine) in the 
specificity pocket, S1’ ((30); for active-site cleft sub-site 
nomenclature, see (35)). It inactivates antimicrobial peptide 
LL-37 and integrants of the complement system, including 
ficolin-2, ficolin-3, C4 and C5, by proteolysis and may thus 
contribute to evasion of the innate host immune response 
(29,31). Karilysin is sequentially and evolutionarily closer 
to MMPs from winged insects that are transmission vectors 
of human diseases (47% sequence identity with Dm1 from 
Aedes aegypti and Anopheles gambiae; (9)) and mammals 
(44% identity with human MMP-11, -13, and -20; (9)) than 
to the few other bacterial sequences found in genomic 
sequences. Accordingly it was likewise suggested that it 
may be the result of horizontal gene transfer of an MMP 
gene from an animal to an intimate bacterial pathogen, 
which inhabits a biofilm on the tooth surface in humans 
(9). 
The metzincins are characterized by a consensus 
sequence responsible for binding of the catalytic zinc ion 
(CSBZ), H-E-X-X-H-X-X-[G/N]-X-X-[H/D] (amino acid 
one-letter code; X stands for any residue), and a conserved 
methionine-containing turn, the “Met-turn” (1-5,36). In 
MMPs, the CSBZ encompasses three histidine zinc ligands, 
the general base/acid glutamate for catalysis, and a 
structurally-relevant glycine (3). In addition, the distinct 
MMP paralogs are multi-domain proteins that display a 
disparate domain organization that is the result of 
successive polyplication, gene fusion and exon shuffling 
(11). The only domains common to all animal and plant 
MMPs are a signal peptide, which is removed after 
secretion, a pro-domain and a catalytic domain, as found 
e.g. in human MMP-7 and MMP-26, and in plant MMPs 
(12,16,18).  
Most peptidases are biosynthesized as zymogens 
containing pro-segments, which are required for latency 
maintenance to prevent unbridled activity but also 
sometimes to assist in proper folding of the usually 
downstream catalytic moieties (37-40). Metzincin 
exceptions lacking pro-segments include the 
archaemetzincins, for which no hydrolytic activity has so 
far been reported, i.e. they might not need to be kept latent 
(41,42); the toxilysin EcxA from Escherichia coli, whose 
soluble expression requires co-expression with its cognate 
EcxB subunit, thus pointing to a chaperone-like function 
for this ancillary subunit (43-45); the cholerilysin StcE 
from E. coli, for which an N-terminal immunoglobulin-like 
domain may assist the downstream catalytic moiety in 
proper folding (46); and igalysins, where an all-β-domain 
of similar topology to immunoglobulin-like domains is 
likewise found at the N-terminus of the catalytic moiety 
(see Protein Data Bank [PDB] access codes 4DF9 and 
3P1V, and (5)).  
MMP pro-domains (see Table 1 in (47)) span 60-90 
residues and include a conserved sequence motif, P-R-C-G-
(V/N)-P-D, engaged in a “cysteine-switch” or “Velcro” 
mechanism of latency (10,16,48-51). It has been suggested 
that this mechanism may be shared by variants within other 
metzincin families, for which conserved cysteines were 
described upstream of the catalytic domain, such as the 
ADAMs/adamalysins (motif P-K-M-C-G-V, (8,52-54)), 
leishmanolysins (motif H-R-C-I-H-D; (2)), and pappalysins 
(motif C-G; (55)). In contrast, the 472 residues encoded by 
the karilysin gene (see UniProt sequence database [UP] 
access code D0EM77) only comprise a short 14-residue 
potential pro-peptide—which lacks cysteines—between the 
20-residue signal peptide and the 161-residue mature 
catalytic moiety (Fig. 1A). A C-terminal domain of 277 
residues of unknown function and sequence unrelated to 
any domain found in eukaryotic MMPs completes the 
protein. This strongly suggests a potentially different 
mechanism of latency maintenance, hitherto unseen not 
only in MMPs but also in metzincins in general, as the 
shortest pro-segments described to date are those of 
members of the astacin family, which span >34 residues 
(7,56-58).  
We had previously determined the structure of the 
catalytic domain of karilysin (termed Kly18; (9)). To shed 
light on the molecular determinants of the first mechanism 
of latency maintenance of a bacterial MMP, in this work 
we assayed the possible function of the pro-peptide in 
folding, stability, and activity inhibition of Kly18. We 
further solved the X-ray crystal structure of an active-site 
mutant of a construct spanning the pro-peptide and Kly18 
affecting the catalytic glutamate, pKly18-E156A, to 
circumvent autolysis. The mechanism derived was 
supported by site-directed mutagenesis and it is discussed 
in the context of general MMP latency maintenance. 
EXPERIMENTAL PROCEDURES 
Protein production and purification — The gene 
coding for full-length wild-type T. forsythia pro-karilysin 
without the 20-residue signal peptide (hereafter pKly; 
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52KDa; residues Q21-K472 according to UP D0EM77, see 
also Fig. 1A) was cloned at BamHI and XhoI restriction 
sites into vector pGEX-6P-1 (GE Healthcare) as described 
elsewhere (30). The resulting vector, pKAR1 (see Table 1 
for an overview of vectors and constructs used), confers 
resistance towards ampicillin and attaches an N-terminal 
glutathione-S-transferase (GST) moiety followed by a 
human rhinovirus 3C proteinase (HR3CP) recognition site 
(L-E-V-L-F-Q-↓-G-P; HR3CP cleavage leaves two extra 
residues—underlined—at the N-terminus of the 
recombinant protein after digestion; three extra residues, L-
G-S, are further present due to the cloning strategy). 
Single-residue point mutants pKly-Y35A and pKly-E156A 
(pKAR2 and pKAR3, respectively) were generated using 
the QuikChange Site-Directed Mutagenesis Kit 
(Stratagene) according to the manufacturer’s instructions as 
described (30). Double mutant pKly-D25A+Y35A (pKAR4) 
was similarly generated using pKAR2 as a template. Genes 
coding for the E156A-mutated catalytic domain of karilysin, 
with and without the pro-peptide (hereafter pKly18-E156A 
and Kly18-E156A; 20KDa and 18KDa; residues Q21-S201 
and residues Y35- S201, respectively), were also cloned into 
vector pGEX-6P-1 (pKAR5 and pKAR6, respectively). 
Genes coding for pKly18 and its mutant proteins pKly18-
Y35A and pKly18-D25A+Y35A were cloned into the same 
vector (pKAR7, pKAR8, and pKAR9, respectively) 
following a strategy previously described (59). Genes 
coding for pKly18, pKly18-E156A, Kly18 and Kly18-E156A 
were furthermore cloned at NcoI and XhoI restriction sites 
into vector pCRI-7a (59), which confers resistance towards 
kanamycin and does not attach fusion proteins (pKAR10-
pKAR13, respectively). In these cases, the cloning strategy 
entailed that residues M-G were attached at the N-terminus. 
All constructs were verified by DNA sequencing.   
Proteins encoded by vectors pKAR1-pKAR9 were 
produced by heterologous overexpression in E. coli BL21 
(DE3) cells, which were grown at 37°C in Luria Bertani 
medium supplemented with 100µg/ml ampicillin. Cultures 
were induced at an A600 of 0.8 with 0.2mM isopropyl-β-D-
thiogalactopyranoside (IPTG) and incubated overnight at 
18°C. Purification of wild-type and mutant pKly, and 
subsequent autolysis of the former to obtain Kly18, was 
achieved as described elsewhere (30). In turn, pKly18-
E156A, Kly18-E156A, pKly18-Y35A and pKly18-D25A+Y35A 
were purified as follows. After centrifugation at 7,000xg 
for 30min at 4°C, the pellet was washed twice in 1x PBS, 
and resuspended in the same buffer supplemented with 
EDTA-free protease inhibitor cocktail tablets and DNase I 
(both Roche Diagnostics). Cells were lysed using a cell 
disrupter (Constant Systems, Ltd.) at 1.35Kbar, and the cell 
debris was removed by centrifugation at 40,000xg for 1h at 
4°C. The supernatant was filtered (0.22µm pore size; 
Millipore), and incubated with Glutathione Sepharose 4B 
resin (GE Healthcare). The sample was washed first in 1x 
PBS and then in buffer A (50mM Tris-HCl, 150mM NaCl, 
pH7.5), and eluted by incubation and cleavage with 
HR3CP at 1:20 enzyme:substrate (w/w) ratio for 48h at 
4°C. The protein was concentrated by ultrafiltration, and 
finally purified by size-exclusion chromatography on 
16/600 or 10/300 Superdex 75 columns (GE Healthcare) 
previously equilibrated with buffer B (20mM Tris-HCl, 
pH8.0) or buffer C (20mM Tris-HCl, 150mM NaCl, 
pH7.5).  
Proteins encoded by vectors pKAR10-pKAR13 
were produced in E. coli BL21 (DE3) cells, which were 
grown at 37°C in Luria Bertani medium supplemented with 
30µg/ml kanamycin. Cultures were induced at an A600 of 
0.8 with 0.2-1mM IPTG and incubated either for 5h at 
37°C or overnight at 18°C. Cells were harvested by 
centrifugation at 7,000xg for 30min at 4°C, washed in 
buffer A, resuspended in the same buffer, and further lysed 
in an ice-bath using a digital sonifier (Branson). After 
centrifugation at 15,000xg for 30min at 4°C, both cell 
debris and supernatant were analyzed by 15% Tricine-
SDS-PAGE stained with Coomassie blue. 
Protein identity and purity were assessed by mass 
spectrometry using an Autoflex Bruker apparatus and by 
N-terminal sequencing through Edman degradation at the 
Proteomics Facility of Centro de Investigaciones 
Biológicas (Madrid, Spain). Ultrafiltration steps were 
performed with Vivaspin 15 and Vivaspin 4 filter devices 
of 5-KDa cut-off (Sartorius Stedim Biotech). Approximate 
protein concentration was determined by measuring A280 in 
a spectrophotometer (NanoDrop) using the calculated 
absorption coefficients Ε0.1% = 2.32 and 2.42 for pKly18-
E156A and Kly18-E156A, respectively.   
Autolytic activation and pro-peptide inhibitory 
activity assays —Mutants pKly-Y35A (from pKAR2), 
pKly-D25A+Y35A (pKAR4), and pKly18-Y35A (pKAR8) 
were incubated in buffer B at 37°C and at 0.4mg/ml final 
protein concentration for up to 120h to assay autolysis. 
Reactions were stopped at specific time points by boiling 
aliquots in reducing/denaturing buffer, and samples were 
further analyzed by 10% or 15% Tricine-SDS-PAGE 
stained with Coomassie blue. Kly18, obtained by autolysis 
from pKAR1-encoded protein, was incubated at 
0.025µg/ml final protein concentration for 30min with 0.1-
10mM of peptide Q-R-L-Y-D-N-G-P-L-T (purchased from 
GL Biochem Ltd), which mimics the pro-peptide sequence. 
Proteolytic activity was subsequently measured at 37°C in 
buffer C on substrate Mca-R-P-K-P-V-E-Nva-W-R-
K(dnp)-NH2 (Bachem; at 10µM) in a microplate 
fluorimeter (Infinite M200, Tecan).  
Thermal shift assays — Aliquots were prepared by 
mixing 7.5µl of 300x Sypro Orange dye (Molecular 
Probes) and 42.5µl of either pKly18-E156A (from pKAR5) 
or Kly18-E156A (pKAR6) at 1-2mg/ml in buffer C in the 
absence and in the presence of 1-5mM CaCl2. Four 
replicates of each aliquot were analyzed in an iQ5 Multi 
Color Real Time PCR Detection System (Bio-Rad) in 96-
well PCR plates sealed with optical tape. Samples were 
heated from 30°C to 95°C at 0.5°C/min, and the change in 
absorbance (λex = 490nm; λem = 575nm) was monitored 
over time. The temperature of midtransition (Tm; (60)) was 
determined for both proteins from the inflection point of 
each curve using iQ5 software.  
Crystallization and data collection — 
Crystallization assays of pKAR5-encoded pKly18-E156A 
protein were carried out at the IBMB/IRB Crystallography 
Platform by the sitting-drop vapor diffusion method using 
96x2-well MRC plates (Innovadyne). A TECAN Freedom 
EVO robot was used to prepare reservoir solutions, and a 
Phoenix/RE (Art Robbins) robot or a Cartesian Microsys 
 
López-Pelegrín et al.                                                                                                                                    4 
  
4000 XL (Genomic Solutions) was used for nanodrop 
dispensing. Crystallization plates were stored in Bruker 
steady-temperature crystal farms at 4ºC and 20°C. 
Successful conditions were scaled up to the microliter 
range in 24-well Cryschem crystallization dishes (Hampton 
Research). The best crystals were obtained at 20°C from 
drops containing protein solution (3.75mg/ml in buffer B) 
and 100mM Bis-Tris propane, 200mM potassium 
thiocyanate, 20% (w/v) polyethylene glycol 3,350, pH7.5 
as reservoir solution from 2:1µl drops. Crystals were cryo-
protected with 20% (v/v) glycerol. Diffraction datasets 
were collected at 100K from liquid-N2 flash-cryo-cooled 
crystals (Oxford Cryosystems 700 series cryostream) on a 
Pilatus 6M pixel detector (from Dectris) at beam lines 
ID23-1 and ID29 of the European Synchrotron Radiation 
Facility (ESRF, Grenoble, France) within the Block 
Allocation Group “BAG Barcelona.” Crystals contained 
two molecules per asymmetric unit. Diffraction data were 
integrated, scaled, merged, and reduced with programs 
XDS (61) and XSCALE (62) (see Table 2 for data 
processing statistics of the best dataset). 
Structure solution and refinement — The structure 
of pKly18-E156A was solved by likelihood-scoring 
molecular replacement with program PHASER (63) using 
the coordinates of the protein part only of mature wild-type 
Kly18 (PDB access code 4IN9; (64,65)) as searching 
model. Two solutions were found at final Eulerian angles 
(α, β, γ, in º) of 285.8, 56.7, 97.2 and 76.9, 91.3, 284.2; and 
fractional cell coordinates (x, y, z) of 0.120, -0.017, 0.100 
and 0.997 0.332 0.608, respectively. These solutions gave 
initial Z-scores of 8.5 and 8.3 for the rotation functions, 
and 6.6 and 6.2 for the translation functions, respectively, 
as well as a final log-likelihood gain of 1,120. A 
subsequent density improvement step with ARP/wARP 
(66) rendered an electron density map that enabled 
straightforward chain tracing. Thereafter, manual model 
building with COOT (67,68) alternated with 
crystallographic refinement with programs PHENIX (69) 
and BUSTER/TNT (70,71), which included TLS 
refinement and automatically-determined non-
crystallographic restraints, until completion of the model. 
Both final model chains A and B contained residues Q21-
P199, as well as two zincs and one calcium each. Segment 
V36-G39 of chain A was continuous in the final Fourier map 
but ambiguous as to the position of the side chains. In 
addition, segments Q38-S40 and S54-H57 of chain B were 
traced based on weak electron density to preserve chain 
continuity. P122 and P123 were linked by a cis-peptide bond. 
Three glycerol molecules and 226 solvent molecules 
completed the structure (see Table 2). 
Miscellaneous — Figures were prepared with 
CHIMERA (72). Structural superpositions were performed 
with SSM (73) within COOT, and with LSQKAB (74) and 
ROTMAT within the CCP4 suite of programs (75). Model 
validation was performed with MOLPROBITY (76). The 
interaction surface buried at the interface between the pro-
peptide and the mature enzyme moiety was calculated with 
CNS v. 1.3 (77). The final coordinates of pKly18-E156A are 
deposited with the PDB at www.pdb.org (access code 
4R3V). 
RESULTS AND DISCUSSION 
Roles of the pro-peptide in vitro and in cellula 
— Wild-type karilysin is secreted as a zymogen with a 14-
residue N-terminal pro-peptide (Q21-R-L-Y-D-N-G-P-L-T-
G-D-N-N34), which is cleaved off at position N34-Y35 
during maturation (Fig. 1A). This is the primary activation 
cleavage and it releases an active 48-KDa form (Kly48; 
(30)). In recombinant protein production, subsequent 
cleavages within the C-terminal domain give rise to Kly38 
and, finally, to a stable form of 18KDa (Kly18), which 
corresponds to the isolated mature catalytic domain (CD; 
(28,30,33,78)). These cleavages were shown to be autolytic 
as activation was repressed by general chelating MP 
inhibitors and in the inactive active-site variant, E156A, 
which ablated the catalytic glutamate of the CSBZ 
(1,5,30,79,80). In addition, cleavage-site mutant Y35A, 
which does not match the enzyme’s specificity, was 
activated only slowly when compared with the wild type 
(30,33). 
To assess whether the pro-peptide had a 
chaperone-like function on the downstream catalytic 
moiety, we cloned the genes encoding pKly18-E156A and 
Kly18-E156A in a vector that does not attach a fusion 
protein at the N-terminus that would assist in proper 
folding (pKAR11 and pKAR13, respectively; see 
“Experimental procedures”). We found that the active-site 
mutant pKly18-E156A was successfully overexpressed in 
soluble form (Fig. 1B). In contrast to the zymogen, Kly18-
E156A was produced only in insoluble form (Fig. 1B). 
Moreover, when expressed from the pKAR6 vector, which 
attaches an N-terminal glutathione-S-transferase fusion 
protein (see Table 1), Kly18-E156A was obtained with ∼10-
times lower yield than the pro-protein (vector pKAR5). We 
conclude that the pro-peptide plays a major role in proper 
folding of Kly18 as previously described for other MPs 
such as fragilysin (26,27), funnelin 
metallocarboxypeptidases (79,81,82), and 
ADAMs/adamalysins (54) but not for mammalian MMPs 
(83). 
We further examined the effect of the pro-peptide 
in response to denaturation by a thermal shift assay 
following the thermofluor approach (60). Purified pKly18-
E156A (pKAR5) showed two unfolding transitions 
compatible with unfolding of pro-peptide and CD, with Tm 
values of 60°C±0.5°C and 74°C±0.5°C (Fig. 1C). In 
contrast, the unfolding of purified Kly18-E156A (pKAR6) 
showed a single transition, with a Tm of 49°C±2.2°C. The 
addition of a physiological concentration of calcium 
resulted in a substantial increase in stability of both 
pKly18-E156A and Kly18-E156A. Accordingly, the former 
showed Tm values of 67.5°C±1.7°C and 76.5°C±1.2°C, and 
69.5°C±1.7°C and 79°C±2.2°C, in the presence of 1mM 
and 5mM CaCl2, respectively, whereas those of Kly18-
E156A were 52.5°C±1.2°C and 54.5°C±1°C. This result is 
in agreement with the important role of calcium in Kly18 
activity, as addition of 2-5mM CaCl2 is reported to enhance 
activity about three times (30). Thus, regardless of calcium, 
the 14-residue pro-peptide redounded to a dramatic 
increase in Tm, underpinning that it plays a major role in the 
thermal stability of the zymogen. Finally, we assayed the 
effect of a decapeptide spanning pro-peptide sequence Q21-
T30 on the activity of purified mature Kly18 (pKAR1) in 
the presence of a fluorogenic peptide (Fig. 1D). We 
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observed a weak but consistently concentration-dependent 
inhibitory effect as previously shown for other MPs when 
their pro-peptides or pro-domains were added in trans, 
among others funnelins (79,81), ADAMs/adamalysins (84), 
and mammalian MMPs (85-87).  
Summarizing, the pro-peptide of karilysin is the 
shortest currently described to date for an MP, and it exerts 
all roles, which collectively or selectively had been 
previously described for peptidase pro-peptides or pro-
domains: latency maintenance, folding assistance during 
biosynthesis, stability to thermal denaturation, and 
inhibition of peptidolytic activity (38,39,81). 
Overall structure of pKly18 — Due to rapid 
autolytic processing of recombinant wild-type pro-karilysin 
(30), crystals of pKly18 could only be obtained for an 
inactive variant affecting the catalytic glutamate (pKly18-
E156A), as already reported for other MP zymogens (88-
92). This protein crystallized as monoclinic crystals 
diffracting to 2Å resolution with two molecules per 
asymmetric unit. These were essentially identical (Cα-atom 
rmsd = 0.53Å) except for segments N53-H57 and N34-G39. 
The latter flanks the primary activation cleavage point and 
is flexible. It is stabilized through an interaction with 
segment N87-N89 of the second molecule present in the 
asymmetric unit of the crystal though in different 
conformations in molecules A and B, so the discussion 
hereafter is centered on molecule A if not otherwise stated. 
When two values are indicated, they refer to both 
molecules. 
The protein reveals a compact, almost spherical 
shape of ~40Å in diameter and is subdivided into three 
moieties (Fig. 2A): the N-terminal pro-peptide (Q21-N34), 
and a CD split into a larger N-terminal upper sub-domain 
moiety (Y35-G162; NTS) and a smaller C-terminal lower 
sub-domain moiety (I163-P199; CTS, see also (9,28)) if 
viewed in the standard orientation for MPs (35). NTS and 
CTS conform to the overall fold of vertebrate MMPs 
(47,93) and are separated by a shallow active-site cleft. The 
NTS is an α/β-sandwich consisting of a twisted five-
stranded pleated β-sheet (strands βI-βV; see Fig. 2A), 
which is parallel for its first four strands and antiparallel for 
its lowermost one, βIV. The sheet accommodates on its 
concave side two α-helices (the “backing helix” αA and the 
“active-site helix” αB; for numbering and extension of 
repeating secondary structure elements, see Fig. 2C of (9)). 
The right-handed twist of the helices coincides with the 
right-handed twist of the sheet and both helices’ axes 
intersect the strands of the sheet at an angle Ω ≈ -35º (94). 
The two helices pack against each other interacting through 
A66-A70 of αA and L149-A154 of αB at a crossing angle Ω ≈ -
50º, which corresponds to a class-II helix interaction (94). 
The loop connecting strands βIII and βIV (LβIIIβIV) 
contains the “S-loop” (G100-L115), which encompasses first 
a binding site for a structural zinc (Zn998) and, downstream, 
a binding site for a structural calcium (Ca997; see Fig. 2B). 
The zinc is tetrahedrally coordinated by H102 Nε2, D104 
Oδ2, H117 Nε2, and H133 Nδ1, while the calcium is 
octahedrally coordinated by six oxygens: D109 Oδ1, G110 O, 
T112 O, I114 O, D135 Oδ2, and E138 Oε2 (see Fig. 2B and the 
legend for details). The presence of calcium is consistent 
with its crucial role in catalysis (30) and in protein stability 
(see Fig. 1C). Such calcium is found in mammalian MMP 
structures (47,93), but it was not found in previous mature 
Kly18 structures (see below and (9,28)). At G162 of the 
CSBZ, the polypeptide chains takes a sharp turn and enters 
the CTS (Fig. 2A), which mainly contains the “C-terminal 
helix” αC and the Met-turn—centered on M173—which 
forms a hydrophobic base for the catalytic metal-binding 
site and is required for its integrity in MMPs and 
metzincins in general (47). 
The active-site cleft contains the catalytic zinc ion 
(Zn999) at half width coordinated by the three histidines of 
the CSBZ (H155, H159, and H165) through their Nε2 atoms at 
distances 2.00-2.05Å (Fig. 2A,C). The cleft is top-framed 
on its non-primed side (see (35,95)) by the “upper-rim 
strand” βIV of the NTS β-sheet, which in MMPs binds 
substrates in extended conformation from left to right 
through antiparallel β-ribbon-like interactions. On its 
primed side, the cleft is top-framed by the final stretch of 
the S-loop, termed the “bulge-edge segment” (T112-L115), 
and bottom-framed by the segment bridging the Met-turn 
and helix αC. This segment includes the “S1’-wall forming 
segment” (P175-Y177) at the front and the “specificity loop” 
(G179-Q183) at the back. Together with the first turn of the 
active-site helix αB, the latter structural elements 
contribute to the size and chemical nature of the S1’ pocket, 
which confers specificity to Kly18 and also MMPs in 
general (47,93), here for medium-sized to bulky 
hydrophobic residues (30). Side chains participating in 
pocket shaping include L115, A116, T151, V152, H155, L172, 
Y177 and K181. 
Inhibition by the pro-peptide — The 14-residue 
pro-peptide starts at the front right and runs in extended 
conformation across the active-site cleft, thus blocking 
access to the cleft, though in the opposite direction to a 
substrate, i.e. right to left (Fig. 2A,C). This reverse 
orientation of the pro-peptide in the cleft may contribute to 
attenuate autolysis, as previously suggested for zymogens 
of cysteine peptidases and mammalian MMPs (39). The 
interaction with the CD buries a surface of 2,100±35Å2, 
which is much larger than the average of monomeric 
protein-protein domain intra-chain interfaces (1,193Å2; 
(96)) but is slightly lower than the range of typical MMP-
protein inhibitor interaction surfaces (2,400-2,700Å2; see 
(97)). The interaction includes 13 hydrogen bonds, a 
double salt bridge, one metallorganic bond, and 
hydrophobic carbon-carbon contacts between eight 
residues from the pro-peptide and eleven from the CD (see 
Table 3). Segments involved include almost the entire pro-
peptide (R22-G31) and, from the CD, mainly N111-Y120 from 
the bulge-edge segment and the upper-rim strand, and P175-
Y177 from the S1’-wall forming segment. Further involved 
are Y106, A124, E138 and the zinc-liganding histidine side 
chains. Four inter-main chain hydrogen bonds form on the 
primed side of the cleft (two with the S1’-wall forming 
segment and two with the bulge-edge segment and strand 
βIV) and three more on the upstream non-primed side (with 
βIV and LβIVβV; Fig. 2C). In particular, R22 contacts the 
base of the S-loop: it doubly salt-bridges E138, which is also 
one of the calcium ligands (see above, Table 3 and Fig. 
2B), and hydrogen bonds three carbonyl oxygens of the S-
loop, N111, G113, and T112, which, again, is also a calcium 
ligand. In addition, the R22 carbonyl oxygen binds the S1’-
wall forming segment and its side chain performs a 
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hydrophobic interaction with L115. Accordingly, this 
residue plays a major role in the stabilization of the Ca997 
site and, thus, the zymogen in general, which explains its 
enhanced stability in response to thermal denaturation (see 
above). In addition, superposition of pKly18-E156A onto 
mature Kly18 in complex with a tetrapeptidic cleavage 
product in the primed side (see below) and human MMP-8 
with a modeled substrate traversing its cleft based on 
inhibitor structures (98) indicates that R22 occupies the S3’ 
position of the cleft. 
However, the most important interaction of the 
pro-peptide with the CD is exerted by D25, which 
approaches the catalytic zinc from the top and 
monodentately occupies through its Oδ1 atom the fourth 
position of the tetrahedral coordination sphere of the metal 
(2.00/2.04Å apart; Fig. 2C) further to H155, H159, and H165 
Nε2 atoms. The preceding carbonyl group of Y24 binds 
strand βIV, and its aromatic side chain penetrates the deep 
hydrophobic S1’ pocket, mainly interacting with the H155 
ring face-to-face. The π-rings are ~3.5Å apart and parallel 
but slightly displaced along the ring planes to form a half-
overlapping sandwich, which gives rise to an optimal π-
stacked structure (99). Downstream in the chain, P28 is in a 
pocket, probably S2, framed by H159, E164, and Y120—the 
latter two interact through a tight hydrogen bond (Y120 Oη-
E164 Oε2, 2.61Å). Residue L29 is surrounded by the side 
chains of Y106, H117, and F119, which may feature S3 (Fig. 
2C). After G31, the polypeptide abandons the active-site 
cleft moving outward to reach the primary activation 
cleavage point, N34-Y35 (Fig. 2A), after which the chain 
folds back towards the molecular moiety and enters strand 
βI of the NTS β-sheet. 
A novel activation mechanism in MMPs — 
Previous work had yielded three structures of mature wild-
type Kly18 in complexes with tri- and tetrapeptidic 
cleavage products, as well as an inhibitory tetrapeptide in 
the non-primed side of the cleft (PDB 2XS3, 2XS4, and 
4IN9; (9,28)). These were obtained both in the presence 
and in the absence of magnesium and showed deviating 
chain traces for segment N53-H57 (LβIαA) in the two 
molecules found in the asymmetric unit of the magnesium-
unbound structure (PDB 2XS3; (9)) and in the single 
molecules found in magnesium-bound (PDB 2X4; (9)) and 
inhibitor-bound crystals (PDB 4IN9; (28)). In addition, 
significant differences were also found in the second half 
of the S-loop including the bulge-edge segment, which was 
metal-free in all structures, as the aforementioned 
magnesium—which coincides with a potassium site in the 
inhibitor-bound form—was found on the opposite surface 
of the CD (see Fig. 1A,C in (9) and Fig. 1A in (28)), in a 
place that suggests little if any functional or structural 
relevance. In these structures, either an outward- or an 
inward-folded flap was found for the S-loop (Fig. 1E in (9) 
and Fig. 1D in (28)), which suggests intrinsic flexibility of 
this protein segment to adapt to different substrates. 
Among the distinct Kly18 coordinates, molecule A of the 
magnesium-unbound structure (PDB 2XS3) was chosen 
here for comparison with pKly18-E156A as it showed the 
lowest divergence in the overall chain trace (Fig. 2D-F).  
Superposition revealed that the mature CD is 
preformed in the zymogen and, with some notable local 
exceptions (see below), is uncovered by removal of the 
pro-peptide, as found in mammalian MMPs (47) and other 
MPs such as funnelins (79,82). Removal occurs through 
cleavage at N34-Y35, which is solvent exposed on the 
molecular surface and thus readily accessible for 
processing (Fig. 2A). This explains why the wild-type 
zymogen undergoes rapid autolysis, so it cannot be isolated 
intact (see (30) and first section of “Results and 
discussion”). This was the first cleavage observed in vitro, 
thus termed primary activation cleavage site, and no further 
cleavage was detected either within the pro-peptide or in 
the CD. The site is consistent with most vertebrate MMPs 
being activated at X-F/Y bonds, which are found at similar 
regions in all structures (10). Pro-peptide removal occurs 
under loss of a number of protein-protein interactions (see 
Table 3 and preceding section), which explains why the 
mature enzyme is less stable to thermal denaturation (see 
first section of “Results and discussion”). In particular, R22 
plays a key role in stabilizing the Ca997 site (see above), 
and its removal may contribute to cation-site and S-loop 
flexibility, leading to metal loss. This site is easily created 
from the unbound form by two glycine-mediated main-
chain rotations (peptide flip of bond T112-G113 and ~70º-
rotation of peptide bond G110-N111), so as to orient the 
carbonyl oxygens towards the interior, and cation binding 
should largely compensate for the energetic cost of such 
minor rearrangement. However, the finding that none of the 
mature Kly18 structures—which were partially obtained in 
the presence of calcium, see (9)—contained an intact 
calcium-site supports the requirement of R22 as an 
additional stabilizing factor for site integrity. 
Activation further entails that the position 
occupied by D25 Oδ1 in the ligand sphere of the catalytic 
zinc (see preceding section) is taken over by a catalytic 
solvent molecule, which renders a competent active site 
following an “aspartate-switch” mechanism. Such a 
competent zinc environment has also been reported for 
several mature MPs (see e.g. (64,80,100)). To date, 
aspartate-switch zymogenic mechanisms have been 
described only for astacins (7,88) and fragilysins (26), 
which are only distantly related MPs grouped with MMPs 
within the metzincins. To verify the function of D25 in 
latency in pKly18, we used mutant pKly18-Y35A (pKAR8), 
as the wild-type form (pKAR7) was insoluble. While this 
mutant was produced with a yield similar to that of 
pKly18-E156A and was stable for several days, mutant 
pKly18-D25A+Y35A (pKAR9) was insoluble. We further 
assessed the function of D25 in full-length karilysin using 
the slowly-autolytic mutant pKly-Y35A (pKAR2), as the 
reaction in the wild type is too rapid (30). While pKly-
Y35A was essentially intact after 5 days at 37ºC, pKly-
D25A+Y35A (pKAR4) had been entirely transformed into 
the 38-KDa and 18-KDa forms after this time (Fig. 1E,F). 
Taken together, these results support the essential role of 
D25 in latency maintenance 
As to further changes upon maturation, segment 
P122-A129 from LβIVβV is slightly shifted downwards by 
~2Å and the side chains of Y120 and E164 rotate towards the 
zinc site (Fig. 2E). Activation only entails major 
rearrangement of the new N-terminal segment Y35-S40, on 
the left surface (Fig. 2D,E), which is rotated downward 
around bonds C-Cα and Cα-N of S40. In this way, this 
segment nestles in a surface cavity framed by helix αC and 
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the first segment of the CTS between G162, and the “family 
specific residue”, which is a serine in MMPs ((1,101); here 
S166). This entails that the new α-amino group of Y35, 
which is translated 25Å, establishes an intra-molecular salt 
bridge with D187 of αC, which is vaguely reminiscent of the 
activation of trypsin-like serine peptidases (102). D187, in 
turn, is itself further bound to S166 and is adjacent to a 
second aspartate, D188, which binds two main-chain amides 
of the Met-turn. This electrostatic network is characteristic 
of physiologically-relevant mature MMPs, also referred to 
as “superactive forms” (47,103). With the exception of the 
mature N-terminal fragment, the rest of this electrostatic 
network is already present in the zymogen (Fig. 2E). 
Intensive studies of the activation of mammalian 
MMPs have produced the structures of pro-MMP-1 (PDB 
1SU3; (90)), pro-MMP-3 (PDB 1SLM; (104)), pro-MMP-9 
(PDB 1L6J; (105)), and pro-MMP-2 (PDB 1EAK; (89)). 
These studies revealed that the mammalian MMP 
zymogens contain a pre-formed competent protease moiety 
and true pro-domains, which span between 66 and 91 
residues, as shown for pro-MMP-2 (Fig. 3A) (47). The pro-
domains include elongated N-terminal extensions that may 
interact with ancillary domains, such as the fibronectin 
type-II insertions found in MMP-2 and MMP-9, followed 
by globular cores of ~55 residues. These are made up of 
three α-helices that are arranged around a three-fold axis 
with a left-handed twist.  
The pro-domain globular core serves as a scaffold 
to place a downstream peptide, which runs in extended 
conformation in the opposite direction to a bound substrate 
and thus blocks the active-site cleft (Fig. 3A,B). This 
peptide encompasses the conserved motif involved in 
cysteine-switch or Velcro latency characteristic of animal 
and plant MMPs (48-50), P100-R-C-G-N-P-D106 (MMP-2 
residues in italics; see PDB 1EAK and UP P08253), which 
is equivalent to pKly18 segment L23-Y-D-N-G-P-L29 (Fig. 
3C,D). Both the cysteine- and aspartate-switch motif show 
an intricate electrostatic network producing a unique 
scaffold to interact with the mature catalytic domain 
moiety. In contrast to pKly18, where the first cleavage 
occurs in the primary activation cleavage site, however, 
classical mammalian pro-MMPs are activated by 
conformational changes in the pro-domain induced by 
cleavage in a so-called “bait region” by several peptidases 
such as trypsin, plasmin, and other MMPs. Activation 
follows a “stepwise activation” process to eventually yield 
the final cleavage site X-F/Y accessible for processing and 
dissociation of cysteine and zinc to generate a functional 
active site (48,49,51,106-108). As in Kly18, after cleavage 
at N109-Y110, the new N-terminus is rearranged and 
participates in the electrostatic network centered on the 
conserved aspartate of helix αC, D346 in MMP-2.  
Conclusions — This examination of the structure 
and function of the zymogen of the first bacterial MMP to 
be studied biochemically has uncovered several features of 
the activation mechanism of pKly18, which are shared with 
animal and plant MMPs: (i) the relevant cleavage site is X-
F/Y; (ii) the scissile bond is located in similar regions of 
the structure; (iii) activation entails rearrangement of the 
segment equivalent to Y35-S40 to yield a salt-bridge 
between the new α-amino group and the first of two 
conserved aspartates in helix αC; (iv) this aspartate is 
bound to the family-specific serine; (v) the aspartate 
immediately downstream binds two main-chain amides of 
the Met-turn; (vi) the inhibitory segments runs across the 
cleft in the opposite direction to a genuine substrate and 
metal blockage occurs through the side chain of an 
intervening residue, not through a chain terminus; and (vii) 
the catalytic moiety is largely preformed in the zymogen. 
All these features are related to the highly conserved CD 
itself. In contrast, all the features of the mechanism related 
to the segment preceding this conserved CD diverge: (i) in 
pKly the pro-peptide spans just 14 residues and does not 
contain repetitive secondary structure elements, while 
vertebrate and plant MMPs feature a true protein pro-
domain that folds into a pseudosymmetric three-helix 
bundle followed by a segment in extended conformation; 
(ii) no relevant sequence identity is found between the pro-
regions; (iii) in eukaryotic MMPs activation occurs through 
a cysteine-switch mechanism exerted by residues from a 
conserved sequence motif, while in pKly18 this motif is 
absent and activation follows an aspartate-switch 
mechanism; (iv) multiple cleavages are apparently required 
in eukaryotic MMPs to liberate the CD while a single 
cleavage suffices in pKly; and (v) the pro-domain is not 
required for (re)folding of the catalytic moieties in 
eukaryotic MMPs while it is in karilysin. In addition, pKly 
shares parts of its mechanism of latency with otherwise 
unrelated MPs from the astacin and fragilysin families. 
Accordingly, this overall novel mechanism unveiled for 
MMPs supports previous hypotheses, according to which 
Kly18 originated from an animal MMP CD co-opted 
through horizontal gene transfer by T. forsythia. This 
transfer was fostered by the intimate coexistence of the 
latter with the human blood-irrigated gingival crevice. 
Subsequently, Kly18 would have evolved in a bacterial 
environment, where it was furnished with unique flanking 
domains that contribute to a mechanism of zymogenicity 
similar to distantly related MPs only (9). 
 
 
López-Pelegrín et al.                                                                                                                                    2 
  
REFERENCES  
1. Bode, W., Gomis-Rüth, F. X., and Stöcker, W. (1993) Astacins, serralysins, snake venom and matrix 
metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and 
should be grouped into a common family, the ´metzincins´. FEBS Lett. 331, 134-140 
2. Gomis-Rüth, F. X. (2003) Structural aspects of the metzincin clan of metalloendopeptidases. Mol. Biotech. 24, 157-202 
3. Gomis-Rüth, F. X. (2009) Catalytic domain architecture of metzincin metalloproteases. J. Biol. Chem. 284, 15353-
15357 
4. Stöcker, W., Grams, F., Baumann, U., Reinemer, P., Gomis-Rüth, F. X., McKay, D. B., and Bode, W. (1995) The 
metzincins - Topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins 
(collagenases) define a superfamily of zinc-peptidases. Prot. Sci. 4, 823-840 
5. Cerdà-Costa, N., and Gomis-Rüth, F. X. (2014) Architecture and function of metallopeptidase catalytic domains. Prot. 
Sci. 23, 123-144 
6. Balaban, N. P., Rudakova, N. L., and Sharipova, M. R. (2012) Structural and functional characteristics and properties of 
metzincins. Biochemistry (Moscow) 77, 119-127 
7. Stöcker, W., and Gomis-Rüth, F. X. (2013) Astacins:Pproteases in development and tissue differentiation. in Proteases: 
Structure and Function. (Brix, K., and Stöcker, W. eds.), Springer Verlag, Vienna. pp 235-263 
8. Gomis-Rüth, F. X. (2013) Zinc adamalysins. in Encyclopedia of Metalloproteins (Uversky, V. N., Kretsinger, R. H., 
and Permyakov, E. A. eds.), Springer Verlag, Heidelberg. pp 2345-2349 
9. Cerdà-Costa, N., Guevara, T., Karim, A. Y., Ksiazek, M., Nguyen, K. A., Arolas, J. L., Potempa, J., and Gomis-Rüth, 
F. X. (2011) The structure of the catalytic domain of Tannerella forsythia karilysin reveals it is a bacterial xenologue of 
animal matrix metalloproteinases. Mol. Microbiol. 79, 119-132 
10. Sang, Q.-X. A., and Douglas, D. A. (1996) Computational sequence analysis of matrix metalloproteinases. J. Prot. 
Chem. 15, 137-160 
11. Fanjul-Fernández, M., Folgueras, A. R., Cabrera, S., and López-Otín, C. (2010) Matrix metalloproteinases: evolution, 
gene regulation and functional analysis in mouse models. Biochim. Biophys. Acta - Mol. Cell res. 1803, 3-19 
12. Marino, G., and Funk, C. (2012) Matrix metalloproteinases in plants: a brief overview. Physiol. Plant. 145, 196-202 
13. de Souza, S. J., and Brentani, R. (1993) Sequence homology between a bacterial metalloproteinase and eukaryotic 
matrix metalloproteinases. J. Mol. Evol. 36, 596-598 
14. Murphy, G. J., Murphy, G., and Reynolds, J. J. (1991) The origin of matrix metalloproteinases and their familial 
relationships. FEBS Lett. 289, 4-7 
15. Jackson, B. C., Carpenter, C., Nebert, D. W., and Vasiliou, V. (2010) Update of human and mouse forkhead box (FOX) 
gene families. Hum. Genomics 4, 345-352 
16. Massova, I., Kotra, L. P., Fridman, R., and Mobashery, S. (1998) Matrix metalloproeinases : structures, evolution, and 
diversification. FASEB J. 12, 1075-1095 
17. Angerer, L., Hussain, S., Wei, Z., and Livingston, B. T. (2006) Sea urchin metalloproteases: a genomic survey of the 
BMP-1/tolloid-like, MMP and ADAM families. Dev. Biol. 300, 267-281 
18. Das, S., Mandal, M., Chakraborti, T., Mandal, A., and Chakraborti, S. (2003) Structure and evolutionary aspects of 
matrix metalloproteinases: a brief overview. Mol. Cell. Biochem. 253, 31-40 
19. Keeling, P. J. (2009) Functional and ecological impacts of horizontal gene transfer in eukaryotes. Curr. Opin. Genet. 
Dev. 19, 613-619 
20. Anderson, M. T., and Seifert, H. S. (2011) Opportunity and means: horizontal gene transfer from the human host to a 
bacterial pathogen. mBio 2, e00005-00011 
21. Moncrief, J. S., Duncan, A. J., Wright, R. L., Barroso, L. A., and Wilkins, T. D. (1998) Molecular characterization of 
the fragilysin pathogenicity islet of enterotoxigenic Bacteroides fragilis. Infect. Immun. 66, 1735-1739 
22. Klein, T., and Bischoff, R. (2011) Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: 
biological function and structure. J. Proteome Res. 10, 17-33 
23. Takeda, S., Takeya, H., and Iwanaga, S. (2012) Snake venom metalloproteinases: Structure, function and relevance to 
the mammalian ADAM/ADAMTS family proteins. Biochim. Biophys. Acta 1824, 164-176 
24. Edwards, D. R., Handsley, M. M., and Pennington, C. J. (2008) The ADAM metalloproteinases. Mol. Aspects Med. 29, 
258-289 
25. Gomis-Rüth, F. X., Meyer, E. F., Kress, L. F., and Politi, V. (1998) Structures of adamalysin II with peptidic inhibitors. 
Implications for the design of tumor necrosis factor α convertase inhibitors. Prot. Sci. 7, 283-292 
26. Goulas, T., Arolas, J. L., and Gomis-Rüth, F. X. (2010) Structure, function and latency regulation of a bacterial 
enterotoxin potentially derived from a mammalian adamalysin/ADAM xenolog. Proc. Natl. Acad. Sci. USA 108, 1856-
1861 
27. Goulas, T., and Gomis-Rüth, F. X. (2013) 186. Fragilysin. in Handbook of proteolytic enzymes. (Rawlings, N. D., and 
Salvesen, G. S. eds.), 3rd Ed., Academic Press, Oxford. pp 887-891 
28. Guevara, T., Ksiazek, M., Skottrup, P. D., Cerda-Costa, N., Trillo-Muyo, S., de Diego, I., Riise, E., Potempa, J., and 
Gomis-Rüth, F. X. (2013) Structure of the catalytic domain of the Tannerella forsythia matrix metallopeptidase 
karilysin in complex with a tetrapeptidic inhibitor. Acta Crystallogr. sect. F 69, 472-476 
 
López-Pelegrín et al.                                                                                                                                    3 
  
29. Jusko, M., Potempa, J., Karim, A. Y., Ksiazek, M., Riesbeck, K., Garred, P., Eick, S., and Blom, A. M. (2012) A 
metalloproteinase karilysin present in the majority of Tannerella forsythia isolates inhibits all pathways of the 
complement system. J. Immunol. 188, 2338-2349 
30. Karim, A. Y., Kulczycka, M., Kantyka, T., Dubin, G., Jabaiah, A., Daugherty, P. S., Thogersen, I. B., Enghild, J. J., 
Nguyen, K. A., and Potempa, J. (2010) A novel matrix metalloprotease-like enzyme (karilysin) of the periodontal 
pathogen Tannerella forsythia ATCC 43037. Biol. Chem. 391, 105-117 
31. Koziel, J., Karim, A. Y., Przybyszewska, K., Ksiazek, M., Rapala-Kozik, M., Nguyen, K. A., and Potempa, J. (2010) 
Proteolytic inactivation of LL-37 by karilysin, a novel virulence mechanism of Tannerella forsythia. J. Innate Immun. 
2, 288-293 
32. Potempa, J., Gomis-Rüth, F. X., and Karim, A. Y. (2013) Chapter 185 - Karilysin. in Handbook of proteolytic enzymes. 
(Rawlings, N. D., and Salvesen, G. S. eds.), 3rd Ed., Academic Press, Oxford. pp 883-886 
33. Skottrup, P. D., Sorensen, G., Ksiazek, M., Potempa, J., and Riise, E. (2012) A phage display selected 7-mer peptide 
inhibitor of the Tannerella forsythia metalloprotease-like enzyme karilysin can be truncated to Ser-Trp-Phe-Pro. PloS 
one 7, e48537 
34. Pomerantsev, A. P., Pomerantseva, O. M., Moayeri, M., Fattah, R., Tallant, C., and Leppla, S. H. (2011) A Bacillus 
anthracis strain deleted for six proteases serves as an effective host for production of recombinant proteins. Prot. Expr. 
Purif. 80, 80-90 
35. Gomis-Rüth, F. X., Botelho, T. O., and Bode, W. (2012) A standard orientation for metallopeptidases. Biochim. 
Biophys. Acta 1824, 157-163 
36. Stöcker, W., and Bode, W. (1995) Structural features of a superfamily of zinc-endopeptidases: the metzincins. Curr. 
Opin. Struct. Biol. 5, 383-390 
37. Stroud, R. M., Kossiakoff, A. A., and Chambers, J. L. (1977) Mechanisms of zymogen activation. Annu. Rev. Biophys. 
Bioeng. 6, 177-193 
38. Bryan, P. N. (2002) Prodomains and protein folding catalysis. Chem. Rev. 102, 4805-4816 
39. Khan, A. R., and James, M. N. (1998) Molecular mechanisms for the conversion of zymogens to active proteolytic 
enzymes. Prot. Sci. 7, 815-836 
40. Baker, D., Shiau, A. K., and Agard, D. A. (1993) The role of pro regions in protein folding. Current opinion in cell 
biology 5, 966-970 
41. Graef, C., Schacherl, M., Waltersperger, S., and Baumann, U. (2012) Crystal structures of archaemetzincin reveal a 
moldable substrate-binding site. PloS one 7, e43863 
42. Waltersperger, S., Widmer, C., Wang, M., and Baumann, U. (2010) Crystal structure of archaemetzincin AmzA from 
Methanopyrus kandleri at 1.5 Å resolution. Proteins 78, 2720-2723 
43. Ng, N., Littler, D., Le Nours, J., Paton, A. W., Paton, J. C., Rossjohn, J., and Beddoe, T. (2013) Cloning, expression, 
purification and preliminary X-ray diffraction studies of a novel AB(5) toxin. Acta Crystallogr. sect. F 69, 912-915 
44. Ng, N. M., Littler, D. R., Paton, A. W., Le Nours, J., Rossjohn, J., Paton, J. C., and Beddoe, T. (2013) EcxAB Is a 
founding member of a new family of metalloprotease AB toxins with a hybrid cholera-like B subunit. Structure 21, 
2003-2013 
45. Gomis-Ruth, F. X. (2013) A different look for AB5 toxins. Structure 21, 1909-1910 
46. Yu, A. C., Worrall, L. J., and Strynadka, N. C. (2012) Structural insight into the bacterial mucinase StcE essential to 
adhesion and immune evasion during enterohemorrhagic E. coli infection. Structure 20, 707-717 
47. Tallant, C., Marrero, A., and Gomis-Rüth, F. X. (2010) Matrix metalloproteinases: fold and function of their catalytic 
domains. Biochim. Biophys. Acta - Mol. Cell Res. 1803, 20-28 
48. Springman, E. B., Angleton, E. L., Birkedal-Hansen, H., and Van Wart, H. E. (1990) Multiple modes of activation of 
latent human fibroblast collagenase : evidence for the role of a Cys73 active-site zinc complex in latency and a 
"cysteine switch" mechanism for activation. Proc. Natl. Acad. Sci. USA 87, 364-368 
49. van Wart, H. E., and Birkedal-Hansen, H. (1990) The cysteine switch : a principle of regulation of metalloproteinase 
activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA 87, 
5578-5582 
50. Vallee, B. L., and Auld, D. S. (1990) Zinc coordination, function, and structure of zinc enzymes and other proteins. 
Biochemistry 29, 5647-5659 
51. Rosenblum, G., Meroueh, S., Toth, M., Fisher, J. F., Fridman, R., Mobashery, S., and Sagi, I. (2007) Molecular 
structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase zymogen: challenging the 
cysteine switch dogma. J. Am. Chem. Soc. 129, 13566-13574 
52. Loechel, F., Overgaard, M. T., Oxvig, C., Albrechtsen, R., and Wewer, U. M. (1999) Regulation of human ADAM 12 
protease by the prodomain. Evidence for a functional cysteine switch. J. Biol. Chem. 274, 13427-13433 
53. Grams, F., Huber, R., Kress, L. F., Moroder, L., and Bode, W. (1993) Activation of snake venom metalloproteinases by 
a cysteine switch-like mechanism. FEBS Lett. 335, 76-80 
54. Leonard, J. D., Lin, F., and Milla, M. E. (2005) Chaperone-like properties of the prodomain of TNFα-converting 
enzyme (TACE) and the functional role of its cysteine switch. Biochem. J. 387, 797-805 
55. Tallant, C., García-Castellanos, R., Seco, J., Baumann, U., and Gomis-Rüth, F. X. (2006) Molecular analysis of 
ulilysin, the structural prototype of a new family of metzincin metalloproteases. J. Biol. Chem. 281, 17920-17928 
 
López-Pelegrín et al.                                                                                                                                    4 
  
56. Gomis-Rüth, F. X., Trillo-Muyo, S., and Stöcker, W. (2012) Functional and structural insights into astacin 
metallopeptidases. Biol. Chem. 393, 1027-1041 
57. Sterchi, E. E., Stöcker, W., and Bond, J. S. (2008) Meprins, membrane-bound and secreted astacin metalloproteinases. 
Mol. Aspects Med. 29, 309-328 
58. Bond, J. S., and Beynon, R. J. (1995) The astacin family of metalloendopeptidases. Prot. Sci. 4, 1247-1261 
59. Goulas, T., Cuppari, A., García-Castellanos, R., Snipas, S., Glockshuber, R., Arolas, J. L., and Gomis-Rüth, F. X. 
(2014) The pCri System: a vector collection for recombinant protein expression and purification. PloS one 9, in press 
60. Ericsson, U. B., Hallberg, B. M., DeTitta, G. T., Dekker, N., and Nordlund, P. (2006) Thermofluor-based high-
throughput stability optimization of proteins for structural studies. Anal. Biochem. 357, 289-298 
61. Kabsch, W. (2010) XDS. Acta Crystallogr. sect. D 66, 125-132 
62. Kabsch, W. (2010) Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. sect. D 66, 133-
144 
63. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser 
crystallographic software. J. Appl. Crystallogr. 40, 658-674 
64. Bode, W., Gomis-Rüth, F. X., Huber, R., Zwilling, R., and Stöcker, W. (1992) Structure of astacin and implications for 
activation of astacins and zinc-ligation of collagenases. Nature 358, 164-167 
65. Gomis-Rüth, F. X., Stöcker, W., Huber, R., Zwilling, R., and Bode, W. (1993) Refined 1.8 Å X-ray crystal structure of 
astacin, a zinc-endopeptidase from the crayfish Astacus astacus L. Structure determination, refinement, molecular 
structure and comparison with thermolysin. J. Mol. Biol. 229, 945-968 
66. Cohen, S. X., Ben Jelloul, M., Long, F., Vagin, A., Knipscheer, P., Lebbink, J., Sixma, T. K., Lamzin, V. S., 
Murshudov, G. N., and Perrakis, A. (2008) ARP/wARP and molecular replacement: the next generation. Acta 
Crystallogr. sect. D 64, 49-60 
67. Debreczeni, J. É., and Emsley, P. (2012) Handling ligands with Coot. Acta Crystallogr. sect. D 68, 425-430 
68. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. Acta Crystallogr. 
sect. D 66, 486-501 
69. Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. 
C., Urzhumtsev, A., Zwart, P. H., and Adams, P. D. (2012) Towards automated crystallographic structure refinement 
with phenix.refine. Acta Crystallogr. sect. D 68, 352-367 
70. Smart, O. S., Womack, T. O., Flensburg, C., Keller, P., Paciorek, W., Sharff, A., Vonrhein, C., and Bricogne, G. (2012) 
Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta 
Crystallogr. sect. D 68, 368-380 
71. Blanc, E., Roversi, P., Vonrhein, C., Flensburg, C., Lea, S. M., and Bricogne, G. (2004) Refinement of severely 
incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr. sect. D 60, 2210-2221 
72. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) 
UCSF Chimera - A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 
73. Krissinel, E., and Henrick, K. (2004) Secondary-structure matching (SSM), a new tool for fast protein structure 
alignment in three dimensions. Acta Crystallogr. sect. D 60, 2256-2268 
74. Kabsch, W. (1976) A solution for the best rotation to relate two sets of vectors. Acta crystallogr. sect. A 32, 922-923 
75. Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., 
Leslie, A. G., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., Read, R. 
J., Vagin, A., and Wilson, K. S. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr. sect. 
D 67, 235-242 
76. Chen, V. B., Arendall, W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., 
Richardson, J. S., and Richardson, D. C. (2010) MolProbity: all-atom structure validation for macromolecular 
crystallography. Acta Crystallogr. sect. D 66, 12-21 
77. Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J.-S., Kuszewski, 
J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography & NMR 
System : a new software suite for macromolecular structure determination. Acta Crystallogr. sect. D 54, 905-921 
78. Cerdà-Costa, N., and Gomis-Rüth, F. X. (2014) Architecture and function of metallopeptidase catalytic domains. Prot. 
Sci. 23, 123-144 
79. Gomis-Rüth, F. X. (2008) Structure and mechanism of metallocarboxypeptidases. Crit. Rev. Biochem. Mol. Biol. 43, 
319-345 
80. Matthews, B. W. (1988) Structural basis of the action of thermolysin and related zinc peptidases. Acc. Chem. Res. 21, 
333-340 
81. Vendrell, J., Querol, E., and Avilés, F. X. (2000) Metallocarboxypeptidases and their protein inhibitors. Structure, 
function and biomedical properties. Biochim. Biophys. Acta 1477, 284-298 
82. Arolas, J. L., and Gomis-Rüth, F. X. (2013) Zinc metallocarboxypeptidases. in Encyclopedia of Metalloproteins 
(Uversky, V. N., Kretsinger, R. H., and Permyakov, E. A. eds.), Springer Verlag, Heidelberg (Germany). pp 2473-2479 
83. Wetmore, D. R., and Hardman, K. D. (1996) Roles of the propeptide and metal ions in the folding and stability of the 
catalytic domain of stromelysin (matrix metalloproteinase 3). Biochemistry 35, 6549-6558 
84. Gonzales, P. E., Solomon, A., Miller, A. B., Leesnitzer, M. A., Sagi, I., and Milla, M. E. (2004) Inhibition of the tumor 
necrosis factor-α-converting enzyme by its pro domain. J. Biol. Chem 279, 31638-31645 
 
López-Pelegrín et al.                                                                                                                                    5 
  
85. Fotouhi, N., Lugo, A., Visnick, M., Lusch, L., Walsky, R., Coffey, J. W., and Hanglow, A. C. (1994) Potent peptide 
inhibitors of stromelysin based on the prodomain region of matrix metalloproteinases. J. Biol. Chem. 269, 30227-30231 
86. Stetler-Stevenson, W. G., Talano, J. A., Gallagher, M. E., Krutzsch, H. C., and Liotta, L. A. (1991) Inhibition of human 
type IV collagenase by a highly conserved peptide sequence derived from its prosegment. The American journal of the 
medical sciences 302, 163-170 
87. Woessner Jr., J. F., and Nagase, H. (2000) Matrix metalloproteinases and TIMPs (Protein Profile Series - Ed. P. 
Sheterline). Oxford University Press, New York 
88. Guevara, T., Yiallouros, I., Kappelhoff, R., Bissdorf, S., Stöcker, W., and Gomis-Rüth, F. X. (2010) Proenzyme 
structure and activation of astacin metallopeptidase. J. Biol. Chem. 285, 13958-13965 
89. Morgunova, E., Tuuttila, A., Bergmann, U., Isupov, M., Lindqvist, Y., Schneider, G., and Tryggvason, K. (1999) 
Structure of human pro-matrix metalloproteinase-2 : Activation mechanism revealed. Science 284, 1667-1670 
90. Jozic, D., Bourenkov, G., Lim, N. H., Visse, R., Nagase, H., Bode, W., and Maskos, K. (2005) X-ray structure of 
human proMMP-1: new insights into procollagenase activation and collagen binding. J. Biol. Chem. 280, 9578-9585 
91. Demidyuk, I. V., Gromova, T. Y., Polyakov, K. M., Melik-Adamyan, W. R., Kuranova, I. P., and Kostrov, S. V. (2010) 
Crystal structure of protealysin precursor: insights into propeptide function. J. Biol. Chem. 285, 2003-2013 
92. Gao, X., Wang, J., Yu, D. Q., Bian, F., Xie, B. B., Chen, X. L., Zhou, B. C., Lai, L. H., Wang, Z. X., Wu, J. W., and 
Zhang, Y. Z. (2010) Structural basis for the autoprocessing of zinc metalloproteases in the thermolysin family. Proc. 
Natl. Acad. Sci. USA 107, 17569-17574 
93. Bode, W., and Maskos, K. (2003) Structural basis of the matrix metalloproteinases and their physiological inhibitors, 
the tissue inhibitors of metalloproteinases. Biol. Chem. 384, 863-872 
94. Chothia, C., Levitt, M., and Richardson, D. (1977) Structure of proteins: packing of α-helices and pleated sheets. 
Proceedings of the National Academy of Sciences of the United States of America 74, 4130-4134 
95. Schechter, I., and Berger, A. (1967) On the size of active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 
27, 157-162 
96. Jones, S., Marin, A., and Thornton, J. M. (2000) Protein domain interfaces: characterization and comparison with 
oligomeric protein interfaces. Prot. Eng. 13, 77-82 
97. Batra, J., Soares, A. S., Mehner, C., and Radisky, E. S. (2013) Matrix metalloproteinase-10/TIMP-2 structure and 
analyses define conserved core interactions and diverse exosite interactions in MMP/TIMP complexes. PloS one 8, 
e75836 
98. Grams, F., Reinemer, P., Powers, J. C., Kleine, T., Pieper, M., Tschesche, H., Huber, R., and Bode, W. (1995) X-ray 
structures of human neutrophil collagenase complexed with peptide thiol inhibitors. Implications for substrate binding 
and rational drug design. Eur. J. Biochem. 228, 830-841 
99. Hunter, C. A., and Sanders, J. K. M. (1990) The natutre of  π-π  interactions. J. Am. Chem. Soc. 112, 5525-5534 
100. Gomis-Rüth, F. X., Kress, L. F., and Bode, W. (1993) First structure of a snake venom metalloproteinase : a prototype 
for matrix metalloproteinases/ collagenases. EMBO J. 12, 4151-4157 
101. Jiang, W., and Bond, J. S. (1992) Families of metalloendopeptidases and their relationships. FEBS Lett. 312, 110-114 
102. Bode, W. (1979) Aktivierung, Aktivität und Inhibierung des Rindertrypsins. Die Naturwissenschaften 66, 251-258 
103. Reinemer, P., Grams, F., Huber, R., Kleine, T., Schnierer, S., Piper, M., Tschesche, H., and Bode, W. (1994) Structural 
implications for the role of the N terminus in the 'superactivation' of collagenases. A crystallographic study. FEBS Lett. 
338, 227-233 
104. Becker, J. W., A.I., M., Rokosz, L. L., Axel, M. G., Burbaum, J. J., Fitzgerald, P. M., Cameron, P. M., Esser, C. K., 
Hagmann, W. K., Hermes, J. D., and Springer, J. P. (1995) Stromelysin-1 : three-dimensional structure of the inhibited 
catalytic domain and of the C-truncated proenzyme. Prot. Sci. 4, 1966-1976 
105. Elkins, P. A., Ho, Y. S., Smith, W. W., Janson, C. A., D'Alessio, K. J., McQueney, M. S., Cummings, M. D., and 
Romanic, A. M. (2002) Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix 
metalloproteinase. Acta Crystallogr. sect. D 58, 1182-1192 
106. Cha, J., Pedersen, M. V., and Auld, D. S. (1996) Metal and pH dependence of heptapeptide catalysis by human 
matrilysin. Biochemistry 35, 15831-15838 
107. Nagase, H. (1997) Activation mechanisms of matrix metalloproteinases. Biol. Chem. 378, 151-160 
108. Nagase, H., Enghild, J. J., Suzuki, K., and Salvesen, G. (1990) Stepwise activation mechanisms of the precursor of 
matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry 29, 5783-
5789 
109. Harding, M. M. (2006) Small revisions to predicted distances around metal sites in proteins. Acta Crystallogr. sect. D 
62, 678-682 
110. Weiss, M. S. (2001) Global indicators of X-ray quality. J. Appl. Cryst. 34, 130-135 
111. Evans, P. (2006) Scaling and assessment of data quality. Acta Crystallogr. sect. D 62, 72-82 
112. Karplus, P. A., and Diederichs, K. (2012) Linking crystallographic model and data quality. Science 336, 1030-1033 
 
 
 
López-Pelegrín et al.                                                                                                                                    6 
  
ACKNOWLEDGMENTS 
We are grateful to the joint IBMB/IRB Automated Crystallography Platform for assistance during crystallization experiments 
and to Robin Rycroft for very helpful contributions to the manuscript. We acknowledge the help provided by local contacts 
at the ESRF synchrotron. The clone for production of human rhinovirus 3C proteinase was a generous gift from Arie Gerlof 
(EMBL, Hamburg). 
FOOTNOTES 
**This study was financially supported in part by grants from European, US American, Polish, Spanish, and Catalan 
agencies (UMO-2012/04/A/NZ1/00051; 2137/7.PR-EU/2011/2; 2975/7.PR/13/2014/2; DE09761; DE022597; FP7-
HEALTH-2010-261460 “Gums&Joints”; FP7-PEOPLE-2011-ITN-290246 “RAPID”; FP7-HEALTH-2012-306029-2 
“TRIGGER”; BFU2012-32862; BIO2013-49320-EXP; CSD2006-00015; and 2014SGR9). Funding for data collection was 
provided in part by ESRF. The Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University is a 
beneficiary of structural funds from the European Union (POIG.02.01.00-12-064/08). 
FIGURE LEGENDS 
Figure 1.  Effect of the Kly18 pro-peptide in vitro and in vivo. (A) Scheme depicting the domain structure of T. 
forsythia karilysin. Numbering according to UP D0EM77. (B) SDS-PAGE of cultures of wild-type and E156A variants of 
pKly18 and Kly18. Lanes 1 and 2, insoluble and soluble fractions of wild-type pKly18 (from pKAR10), respectively. Lanes 
3 and 4, insoluble and soluble fractions of wild-type Kly18 (pKAR12), respectively. Lanes 5 and 6, insoluble and soluble 
fractions of pKly18-E156A (pKAR11), respectively. Lanes 7 and 8, insoluble and soluble fractions of Kly18-E156A 
(pKAR13), respectively. Overexpressed proteins are labeled with an asterisk. (C) Unfolding transition curves showing 
temperature-dependent change in fluorescence of pKly18-E156A (pKAR5; solid line) and Kly18-E156A (pKAR6; dashed line) 
in the absence (black curve) and in the presence of CaCl2 (1mM, red curve; 5mM, green curve). The blank curve is indicated 
with a dotted line. (D) Proteolytic activity of Kly18 (pKAR1) at 37°C using substrate Mca-R-P-K-P-V-E-Nva-W-R-K(dnp)-
NH2 at 10µM in the absence (0) and in the presence of 0.1, 0.5, 1, 2, and 5mM pro-peptide mimic. (E,F) Stability of mutant 
pKly-Y35A (E) and mutant pKly-Y35A+D25A (F) over time. Kly48, Kly38, and Kly18 are indicated by arrows. 
  
Figure 2.  Overall structure of pKly18-E156A. (A) Ribbon-type plot of pKly18-E156A in standard orientation (35). 
Depicted are the pro-peptide (ribbon and carbon atoms in turquoise) and the mature enzyme moiety (β-strands in yellow 
labeled βI-βV; α-helices in salmon labeled αA-αC; and coils and carbon atoms in tan). Further shown are the catalytic zinc 
ion (Zn999; bottom magenta sphere), the structural zinc ion (Zn998; top magenta sphere), and the structural calcium ion (Ca997; 
red sphere), as well as the side chains of the three catalytic zinc ligands (H155, H159, and H165), the Met-turn methionine 
(M173), the alanine replacing the catalytic glutamate (A156), and the residues flanking the primary activation cleavage point, 
N34-Y35. (B) Close-up of the window of (A) as stick model highlighting the structural zinc and calcium sites. Protein 
segments depicted are N101-G105 from the first part of the S-loop (carbons in gold), D109-F119 from the second part of the S-
loop (carbons in sandy brown), H131-E138 from βV-LβVαB (carbons in tan), and the side chain of R22 from the pro-peptide 
(carbons in turquoise). The zinc is bound by H102 Nε2, D104 Oδ2, H117 Nε2, and H133 Nδ1 at distances 1.99-2.06Å, and the 
calcium is bound by D109 Oδ1, G110 O, T112 O, I114 O, D135 Oδ2, and E138 Oε2 at distances 2.34-2.39Å. These distances agree 
with standard zinc- (1.99-2.09Å; (109)) and calcium-binding (2.36-2.39Å; (109)) distance values for oxygens and nitrogens. 
(C) Close-up of (A) in wall-eye stereo centered on the catalytic zinc after a horizontal ~30º-rotation upwards. Selected 
hydrogen and ionic bonds (see also Table 3) are depicted as green lines. Residues and ions labeled in (A) are not labeled here 
for clarity. The pro-peptide is shown in cyan to distinguish it from the mature catalytic moiety (in tan/yellow/orange) and its 
chain direction is pinpointed by a cyan arrow and labels of the N- and C-terminal parts depcited. (D) Superposition in wall-
eye stereo of pKly18-E156A (ribbon in tan for the mature enzyme moiety and in brown for the pro-peptide, zinc ions in 
magenta, and calcium ion in red; stick model for the side chains of S20-Y35 with carbons in brown) and Kly18 (ribbon and 
zinc ions in pink, see PDB 2XS3, molecule A; (9)), which was obtained in a product complex with peptide A-F-T-S bound to 
the primed side of the cleft (stick model with carbons in gold). Y35 is shown for both structures. (E) Detail of (D) in wall-eye 
stereo depicting the large rearrangement of the N-terminus at Y35 after maturation cleavage at N34-Y35. The α-amino group of 
Y35 makes a salt bridge with the side chain of D187 in the mature enzyme. Aside from Y120 and E164 (significantly) and P122-
A129, (slightly; see black arrows), maturation does not entail major conformational rearrangement of the rest of the structure. 
Figure 3.  Structural comparison with mammalian pro-MMPs. (A) Cartoon depicting the structure of pro-MMP-2 
(PDB 1EAK; (89); MMP-2 residues in italics with superscripted numbering), shown only for its CD (Y110-D452 in cyan; the 
fibronectin type-II domains spanning Q219-D392 have been omitted, the black arrows pinpoint the insertion points) and pro-
domain (P43-N109 in pink, without the first eleven residues in extended conformation). The orientation displayed corresponds 
to that of Fig. 2A after applying a horizontal rotation of 15º. Residues of the conserved motif (P100-D106) key for structural 
integrity of the inhibitory segment are depicted for their side chains. (B) Close-up of (A) after removal of pro-domain 
segment P43-N66 to provide insight into the interactions of the conserved motif. Key electrostatic interactions are shown as 
green lines. The catalytic glutamate, E404, is replaced by a glutamine, the histidines from the CSBZ are H403, H407, and H413. 
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(C,D) Scheme depicting the interaction modi of the pro-peptides of pro-MMP-2 through a cysteine-switch mechanism (C) 
and pKly18 through an aspartate-switch mechanism (D). The catalytic zinc ions are shown as magenta spheres and relevant 
interactions are shown as yellow dashed lines. 
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Table 1. Vectors and constructs. 
Name Original vector Antibiotic 
resistance 
Restriction 
sites 
Insert Fusion 
construct 
(N-term.) 
Additional N-
terminal 
residues 
pKAR1 pGEX-GP-1 
(GE Healthcare) 
amp BamHI / 
XhoI 
wt Q21-K472 (pKly) GST + 
HR3CPr 
G-P-L-G-S  * 
pKAR2 pGEX-GP-1 
(GE Healthcare) 
amp BamHI / 
XhoI 
Y35A mut. Q21-K472 (pKly-Y35A) GST + 
HR3CPr 
G-P-L-G-S  * 
pKAR3 pGEX-GP-1 
(GE Healthcare) 
amp BamHI / 
XhoI 
E156A mut. Q21-K472 (pKly-E156A) GST + 
HR3CPr 
G-P-L-G-S  * 
pKAR4 pGEX-GP-1 
(GE Healthcare) 
amp BamHI / 
XhoI 
D25A+Y35A mut. Q21-K472  
(pKly-D25A+Y35A) 
GST + 
HR3CPr 
G-P-L-G-S  * 
pKAR5 pGEX-GP-1 
(GE Healthcare) 
amp BamHI / 
XhoI 
E156A mut. Q21-S201 (pKly18-E156A) GST + 
HR3CPr 
G-P-  * 
pKAR6 pGEX-GP-1 
(GE Healthcare) 
amp BamHI / 
XhoI 
E156A mut. Y35-S201 (Kly18-E156A) GST + 
HR3CPr 
G-P-  * 
pKAR7 pGEX-GP-1 
(GE Healthcare) 
amp BamHI / 
XhoI 
wt Q21-S201 (pKly18) GST + 
HR3CPr 
G-P-  * 
pKAR8 pGEX-GP-1 
(GE Healthcare) 
amp BamHI / 
XhoI 
Y35A mut. Q21-S201 (pKly18-Y35A) GST + 
HR3CPr 
G-P-  * 
pKAR9 pGEX-GP-1 
(GE Healthcare) 
amp BamHI / 
XhoI 
D25A+Y35A mut. Q21-S201 (pKly18-
D25A+Y35A) 
GST + 
HR3CPr 
G-P-  * 
pKAR10 pCRI-7a (59) kan NcoI / 
XhoI 
wt Q21-S201 (pKly18) none G-P-  * 
pKAR11 pCRI-7a (59) kan NcoI / 
XhoI 
E156A mut. Q21-S201 (pKly18-E156A) none M-G- 
pKAR12 pCRI-7a (59) kan NcoI / 
XhoI 
wt Y35-S201 (Kly18) none M-G- 
pKAR13 pCRI-7a (59) kan NcoI / 
XhoI 
E156A mut. Y35-S201 (Kly18-E156A) none M-G- 
amp, ampicillin; GST, glutathione-S-transferase; HR3CP, human rhinovirus 3C peptidase; HR3CPr, recognition sequence for 
human rhinovirus 3C peptidase; kan, kanamycin; mut., mutant; wt, wild-type. 
* After cleavage with HR3CP. 
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Table 2. Crystallographic data. 
Space group / cell constants (a, b, c in Å and β in º)  P21 / 36.18, 121.69, 41.88, 105.26 
Wavelength (Å)  0.97242 
No. of measurements / unique reflections  104,406 / 22,975 
Resolution range (Å) (outermost shell)  60.8 – 2.01 (2.06 – 2.01) 
Completeness (%)   99.8 (96.2) 
Rmerge  a  0.105 (0.534) 
Rr.i.m. (= Rmeas) a / CC(1/2) b  0.116 (0.616) / 99.6 (84.3) 
Average intensity (<[<I> / s(<I>)]>)  10.3 (2.5) 
B-Factor (Wilson) (Å2) / Average multiplicity  29.0 / 4.5 (4.0) 
Resolution range used for refinement (Å)  ∞ – 2.01 
No. of reflections used (test set)  22,047 (741) 
Crystallographic Rfactor (free Rfactor) c  0.165 (0.194) 
No. of protein atoms 
d
 / solvent molecules /  2,843 / 226 / 
     ligands / ions  3 glycerols / 4 zinc, 2 calcium 
Rmsd from target values  
      bonds (Å)  /  angles (°)  0.010 / 0.98 
Overall average B-factor (Å2)  30.8 
Model validation 
e 
      Residues in favored regions / outliers / all residues  345 (97.5%) / 0 / 355 
      Residues with bad bonds / bad angles / poor rotamers / Cβ dev.>0.25Å 0 / 0 / 7 (2.4%) / 0 
Values in parentheses refer to the outermost resolution shell. 
a Rrmerge = ΣhklΣi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl); Rr.i.m.= Σhkl(nhkl /[nhkl-1])1/2 Σi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl); Rp.i.m.= 
Σhkl(1/[nhkl-1])1/2 Σi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl), where Ii(hkl) is the i-th intensity measurement and nhkl the 
redundancy of reflection hkl—including symmetry-related reflections—and <I(hkl)> its average intensity. Rr.i.m. (alias 
Rmeas) and Rp.i.m. are improved multiplicity-weighted indicators of the quality of the data, the redundancy-independent 
merging R factor and the precision-indicating merging R factor. The latter is computed after averaging over multiple 
measurements (for details, see (110,111)).
 b
 According to Karplus & Diederichs (112). c Crystallographic Rfactor = Σhkl 
||Fobs| - k |Fcalc|| / Σhkl |Fobs|, where k is a scaling factor, and Fobs and Fcalc are the observed and calculated structure factor 
amplitudes, respectively. This factor is calculated for the working-set reflections; free Rfactor, same for a test-set of 
reflections (>500) not used during refinement. d Including atoms with double occupancy. e According to 
MOLPROBITY (76). 
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Table 3. Direct interactions between the pro-peptide (PP) and the catalytic domain (CD). 
PP CD 
Distance (Å) 
molecule A / B PP CD  
Hydrogen bonds Hydrophobic carbon-carbon interactions 
R22 Ο Y177 N 2.73 / 2.73 R22 L115  
R22 Nη2 N111 O 3.19 / 3.19 L23 Y176  
R22 Nη2 T112 O 3.20 / 3.21 Y24 H155  
R22 Nη2 G113 O 3.24 / 3.22 Y24 Y177  
R22 Nε G113 O 3.18 / 3.19 D25 I114  
Y24 N P175 O 3.41 / 3.37 G27 H159  
Y24 O L115 N 2.82 / 2.79 G27 H165  
Y24 O A116 N 3.15 / 3.11 P28 Y120  
L29 N A118 O 2.81 / 2.81 P28 H159  
L29 O Y120 N 2.89 / 2.90 L29 Y106  
T30 O Y106 Oη 3.16 / 3.15 L29 H117  
T30 Oγ1 Y106 Oη 3.75 / 4.18 L29 F119  
G31 N A124 O 2.93 / 2.98 T30 Y120  
Salt bridges Metallorganic bonds 
PP CD 
Distance (Å) 
molecule A / B PP CD 
Distance (Å) 
molecule A / B 
R22 Νη2 E138 Οε2 2.85 / 2.85 D25 Oδ1 Zn999 2.00 / 2.04 
R22 Νη1 E138 Οε1 3.08 / 3.01    
 



